1. A category‐free approach to prognostic modelling in aggressive non‐Hodgkin B cell lymphomas based on large patient databases. (June 2017) Authors: Burton, C.; Sha, C.; Barrans, S.; Jack, A.; Painter, D.; Smith, A.; Roman, E.; Crouch, S.; Care, M.; Tooze, R.; Westhead, D. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Large Committed Long‐Term Sink of Carbon due to Vegetation Dynamics. Issue 10 (4th October 2018) Authors: Pugh, T. A. M.; Jones, C. D.; Huntingford, C.; Burton, C.; Arneth, A.; Brovkin, V.; Ciais, P.; Lomas, M.; Robertson, E.; Piao, S. L.; Sitch, S. Journal: Earth's future Issue: Volume 6:Issue 10(2018) Page Start: 1413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A systematic review of the use, quality and effects of pelvic examination in primary care for the detection of gynaecological cancer. (4th July 2018) Authors: Williams, P.; Bond, C. M.; Burton, C.; Murchie, P. Journal: Journal of obstetrics and gynaecology Issue: Volume 38:Number 5(2018) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Cummin, T.E.; Caddy, J.; Mercer, K.; Maishman, T.; Schuh, A.; Lopez Pascua, L.; Collins, G.; McMillan, A.; Ardeshna, K.; Galanopoulous, A.; Burton, C.; Barrans, S.; Griffiths, G.; Johnson, P.; Davies, A.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. (12th June 2019) Authors: Davies, A.J.; Tansley Hancock, O.; Cummin, T.; Caddy, J.; Stanton, L.; Burton, C.; Barrans, S.; Coleman, A.; Osborne, W.; McKay, P.; Griffiths, G.; Johnson, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). (June 2017) Authors: Chen, R.; Gibb, A.L.; Collins, G.P.; Popat, R.; El‐Sharkawi, D.; Burton, C.; Lewis, D.; Miall, F.M.; Forgie, A.; Compagnoni, A.; Andreola, G.; Brar, S.; Thall, A.; Woolfson, A.; Radford, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CAN BASELINE PET‐CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033). (June 2017) Authors: Pike, L.C.; Kirkwood, A.A.; Patrick, P.; Radford, J.; Burton, C.; Stevens, L.; Clifton‐Hadley, L.; Johnson, P.W.; Barrington, S.F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Correspondence article regarding CD68 as a marker of CD8+ lymphoid proliferation suggested by Wobser et al. (14th March 2016) Authors: Lecamwasam, K.; Mathew, B.; Gilson, D.; Burton, C.; Laws, P. Journal: British journal of dermatology Issue: Volume 174:Number 5(2016) Page Start: 1158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Correspondence article regarding CD68 as a marker of CD8+ lymphoid proliferation suggested by Wobser et al. (1st May 2016) Authors: Lecamwasam, K.; Mathew, B.; Gilson, D.; Burton, C.; Laws, P. Journal: British journal of dermatology Issue: Volume 174:Number 5(2016) Page Start: 1158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. CROSS‐PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN a CLINICAL LABORATORY SETTING. (June 2017) Authors: Burton, C.; Barrans, S.; Ahmed, S.; Bentley, M.A.; Clipson, A.; Wang, M.; Taylor, J.; Detute, R.; Westhead, D.R.; Care, M.A.; Du, M.Q.; Davies, A.; Johnson, P.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗